Boehringer terminates Alzheimer’s candidate after Phase 2 failure

pharmafile | February 12, 2018 | News story | Research and Development, Sales and Marketing Alzheimer's, Boehringer Ingelheim, dementia, pharma 

Boehringer Ingelheim has announced its intention to halt development of its candidate BI 409306 in the treatment of Alzheimer’s after it failed to hit its primary endpoints in Phase 2 studies.

In the trials of 457 patients with cognitive impairment as a result of Alzheimer’s disease, the drug failed to show superiority in improving cognition compared to placebo. The studies were part of a greater programme investigating compounds which target malfunctioning of glutamatergic brain circuits. The company said that full details from the studies would be presented at the Alzheimer’s Association International Conference later this year following a full review of the data.

With the Alzheimer’s trial terminated, Boehringer indicated that it will investigate the therapy’s efficacy in schizophrenia instead, focusing on the prevention of the first psychotic episode in patient with the condition. The company will still conduct research into the field of dementia through its GlyT1 inhibitor BI 425809.

“This is what research is about: disappointments are a daily experience in science, but even these clinical trial results will add to the understanding of brain function and contribute to future progress in this area,” commented Jan Poth, Therapeutic Area Head of CNS diseases at Boehringer Ingelheim.

Stephane Pollentier, Head of Medicine, Therapeutic Area CNS, added: “Starting from our systematic neurobiological approach to CNS research, we will continue to build innovative approaches in our clinical trials and help advance the field in collaboration with the wider scientific community. We won’t rest.”

Matt Fellows

Related Content

Otsuka and Lundbeck gain FDA approval for supplemental New Drug Application for dementia drug

Japan-based healthcare company Otsuka Pharmaceutical and Danish pharma company Lundbeck have announced that the US …

Boehringer Ingelheim and Ginkgo Bioworks collaborate over $406m undruggable targets deal

German pharmaceutical company Boehringer Ingelheim (BI) and cell programming and biosecurity platform builder Ginkgo Bioworks …

Eli Lilly to seek FDA approval for experimental Alzheimer’s drug

Eli Lilly plans to seek accelerated FDA approval for its experimental Alzheimer’s drug donanemab, announcing …

Latest content